The purpose of the Administrative Core is to provide all five Projects and the Cores with centralized administrative support, including clinical research management. This collaborative effort requires significant coordination of effort, integration of strategies, monitoring and oversight of various functions, and communication between the investigators. This Core will effectively and efficiently assure proper coordination among all the projects and cores, facilitating communication between investigators and especially promoting the translation of preclinical findings to the clinic. This core will be responsible for record-keeping, maintenance of protocols and their progress reports, generation of yeariy summary reports related correspondence to the NIH, and manuscript preparation. It will also assist each Individual project and core leader in the maintenance and management of their budgets, as well as arrange internal group meetings and scientific advisory board meetings. Additionally, the core will also oversee research nursing and data management for all five Projects, monitoring the timely conduct ofthe clinical studies assuring issue collection and coordinating interaction between the clinical and correlative science.
The translation of novel treatment approaches from the laboratory to the clinic is an increasingly complex undertaking that requires extensive infrastructure. This Core has the overall responsibility for assuring proper coordination, including clinical, scientific, and administrative aspects, among all the Projects and Cores. The tight integration of all the basic, translational, and clinical research initiatives allows the rapid and efficient translation of concepts to laboratory and clinical hypothesis testing.
|Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229|
|Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028|
|Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811|
|Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224|
|Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909|
|Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617|
|Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25|
|Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280|
|Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400|
|Kanakry, Christopher G; Bolaños-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393|
Showing the most recent 10 out of 456 publications